Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review
Tóm tắt
Shock is a serious acute circulatory failure leading to inadequate oxygen delivery to the cells. Its treatment is mainly based on circulating fluid optimization, and vasopressors to provide an adequate mean arterial pressure and microcirculatory flow. Norepinephrine is the drug of choice, but high dosages may be responsible for several side effects, including increased myocardial oxygen consumption, dysrhythmias, and peripheral and organ ischemia. Moreover, some patients are “non-responders” to first-line norepinephrine treatment. Hence, other drugs have been proposed to reach and maintain the hemodynamic target. In general, they are described as catecholamine-sparing agents. Among others, the most used are vasopressin, corticosteroids, and angiotensin II. Methylene blue (MB) represents a further option, even though its use is still a topic of controversy. This review article tries to summarize what is known and unknown about the actions of MB in patients in shock. It reduces excessive production of nitric oxide via blockade of guanylate cyclase in shock states. At present, it appears the MB provides positive results in septic shock, if administered early. Further randomized controlled trials are warranted regarding its use to provide more precise indications to physicians involved in the treatment of such patients.
Tài liệu tham khảo
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–51. https://doi.org/10.1056/NEJMra1208623.
Scheeren TWL, Bakker J, DeBacker D, et al. Current use of vasopressors in septic shock. Ann Intensive Care. 2019;9(1):20. https://doi.org/10.1186/s13613-019-0498-7.
Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009;24(5):293–316. https://doi.org/10.1177/0885066609340519.
Buckley MS, Barletta JF, Smithburger PL, Radosevich JJ, Kane-Gill SL. Catecholamine vasopressor support sparing strategies in vasodilatory shock. Pharmacotherapy. 2019;39(3):382–98. https://doi.org/10.1002/phar.2199.
Varrassi G, Marino B, Cosmi EV. Influence of methylprednisolone sodium succinate on the microcirculation. Acta Anaesth It. 1974;25:159–71.
De Backer D, Foulon P. Minimizing catecholamines and optimizing perfusion. Crit Care. 2019;23(Suppl 1):149. https://doi.org/10.1186/s13054-019-2433-6.
Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018;22(1):174. https://doi.org/10.1186/s13054-018-2102-1.
Vincent JL. Fluid management in the critically ill. Kidney Int. 2019;96(1):52–7. https://doi.org/10.1016/j.kint.2018.11.047.
Hadian M, Pinsky M. Functional hemodynamic monitoring. Curr Opin Crit Care. 2007;13(3):318–23. https://doi.org/10.1097/MCC.0b013e32811e14dd.
Leone M, Asfar P, Radermacher P, Vincent JL, Martin C. Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature. Crit Care. 2015;19(1):101. https://doi.org/10.1186/s13054-015-0794-z.
Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795–815. https://doi.org/10.1007/s00134-014-3525-z.
Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19(Suppl 3):S8. https://doi.org/10.1186/cc14726.
Elbers P, Ince C. Mechanisms of critical illness—classifying microcirculatory flow abnormalities in distributive shock. Crit Care. 2006;10(4):221. https://doi.org/10.1186/cc4969.
Forstermann U, Sessa W. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(829–837):837a–. https://doi.org/10.1093/eurheartj/ehr304.
Cauwels A. Nitric oxide in shock. Kidney Int. 2007;72:557–65. https://doi.org/10.1038/sj.ki.5002340.
Rekatsina M, Paladini A, Piroli A, Zis P, Pergolizzi J, Varrassi G. Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: a narrative review. Adv Ther. 2020;37(1):113–39. https://doi.org/10.1007/s12325-019-01148-5.
Titheradge M. Nitric oxide in septic shock. Biochim Biophys Acta. 1999;1411(2–3):437–55. https://doi.org/10.1016/s0005-2728(99)00031-6.
Su Y. Regulation of endothelial nitric oxide synthase activity by protein–protein interaction. Curr Pharm Des. 2014;20(22):3514–20. https://doi.org/10.2174/13816128113196660752.
Stawicki SP, Sims C, Sarani B, Grossman MD, Gracias VH. Methylene blue and vasoplegia: who, when, and how? Mini Rev Med Chem. 2008;8:472–90. https://doi.org/10.2174/138955708784223477.
Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013;9(3):242–9. https://doi.org/10.1007/s13181-013-0298-7.
Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. J Crit Care. 2020;57:148–56. https://doi.org/10.1016/j.jcrc.2020.02.011.
Evora PRB. Broad spectrum vasopressors support sparing strategies in vasodilatory shock beyond the vascular receptors. Chest. 2020;157(2):471–2. https://doi.org/10.1016/j.chest.2019.08.2211.
Evora PRB, Alves Junior L, Ferreira CA, et al. Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised. Rev Bras Cir Cardiovasc. 2015;30(1):84–92. https://doi.org/10.5935/1678-9741.20140115.
Kavanaugh M, Berumen J, Chu F, Yin J, Beitler J. Methylene blue utilization for refractory septic shock in the setting of cirrhosis as a bridge to successful liver-kidney transplant: case report and review of the literature. Chest. 2015;148(4, Suppl):206A. https://doi.org/10.1378/chest.2267413.
Vilalva KH, Mumic FT, Silveira MRG, Mente ED, Evora PRB, Castro e Silva O. Use of methylene blue to treat hypovolemic shock followed by ischemia-reperfusion injury in the postoperative orthotopic liver transplant patient: a case report. Exp Clin Transplant. 2018;16(4):511–4. https://doi.org/10.6002/ect.2016.0041.
Peer G, Itzhakov E, Wollman Y, et al. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant. 2001;16(7):1436–41. https://doi.org/10.1093/ndt/16.7.1436.
Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002;30(6):755–62. https://doi.org/10.1177/0310057X0203000606.
Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001;29(10):1860–7. https://doi.org/10.1097/00003246-200110000-00002.
Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999;32(12):1505–13. https://doi.org/10.1590/s0100-879x1999001200009.
Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med. 2002;30(10):2271–7. https://doi.org/10.1097/00003246-200210000-00015.
Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J. 1996;72(852):612–4. https://doi.org/10.1136/pgmj.72.852.612.
Park B-K, Shim T-S, Lim C-M, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med. 2005;20(2):123–8. https://doi.org/10.3904/kjim.2005.20.2.123.
Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care. 1998;13(4):164–8. https://doi.org/10.1016/s0883-9441(98)90001-6.
Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995;21(12):1027–31. https://doi.org/10.1007/BF01700666.
Dumbarton TC, Minor S, Yeung CK, Green R. Prolonged methylene blue infusion in refractory septic shock: a case report. Can J Anesth. 2011;58(4):401–5. https://doi.org/10.1007/s12630-011-9458-x.
Zhang X, Gao Y, Pan P, Wang Y, Li W, Yu X. Methylene blue in the treatment of vasodilatory shock: a meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29(11):982–7. https://doi.org/10.3760/cma.j.issn.2095-4352.2017.11.005.
Evora PRB, de Freitas Ribeiro PJ, de Andrade Vicente WV, et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev Bras Cir Cardiovasc. 2009;24(3):279–88. https://doi.org/10.1590/s0102-76382009000400005.
Evora PRB. Methylene blue does not have to be considered only as rescue therapy for distributive shock. J Med Toxicol. 2013;9(4):426. https://doi.org/10.1007/s13181-013-0333-8.
Belletti A, Musu M, Silvetti S, et al. Non-adrenergic vasopressors in patients with or at risk for vasodilatory shock. A systematic review and meta-analysis of randomized trials. PLoS One. 2015;10(11):e0142605. https://doi.org/10.1371/journal.pone.0142605.
Porizka M, Kopecky P, Dvorakova H, et al. Methylene blue administration in patients with refractory distributive shock—a retrospective study. Sci Rep. 2020;10(1):1828. https://doi.org/10.1038/s41598-020-58828-4.
Manji F, Benjamin Wierstra B, Posadas J. Severe undifferentiated vasoplegic shock refractory to vasoactive agents treated with methylene blue. Case Rep Crit Care. 2017;2017:8747326. https://doi.org/10.1155/2017/8747326.
Oliveira Neto AM, Duarte NM, Vicente WVA, Viaro F, Evora PRB. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit. 2003;9(11):CS102–CS106.
Fisher J, Taori G, Braitberg G, Graudins A. Methylene blue used in the treatment of refractory shock resulting from drug poisoning. Clin Toxicol. 2014;52:63–5. https://doi.org/10.3109/15563650.2013.870343.
Graham RE, Cartner M, Winearls J. A severe case of vasoplegic shock following metformin overdose successfully treated with methylene blue as a last line therapy. BMJ Case Rep. 2015;2014:bcr201521022. https://doi.org/10.1136/bcr-2015-210229.
Aggarwal N, Kupfer Y, Seneviratne C, Tessler S. Methylene blue reverses recalcitrant shock in β-blocker and calcium channel blocker overdose. BMJ Case Rep. 2013;2013:bcr2012007402. https://doi.org/10.1136/bcr-2012-007402.
Laes JR, Williams DM, Cole JB. Improvement in hemodynamics after methylene blue administration in drug-induced vasodilatory shock: a case report. J Med Toxicol. 2015;11(4):460–3. https://doi.org/10.1007/s13181-015-0500-1.
Ranieri VM, Brienza N, Santostasi S, et al. Impairment of lung and chest wall mechanics in patients with acute respiratory distress syndrome: role of abdominal distension. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1082–91.
McCartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia: methylene blue to the rescue! Curr Opin Anesthesiol. 2017;31(1):43–9. https://doi.org/10.1097/ACO.0000000000000548.